Screener
Lexicon Pharmaceuticals LXRX Business Segments — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001062822-26-000117
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net product revenue | $680 | $1,322 | $1,770 | $2,584 |
| Licensing and milestone revenue | — | 27,544 | 20,000 | 27,544 |
| Royalties and other revenue | 12 | — | 24 | — |
| Total revenues | 692 | 28,866 | 21,794 | 30,128 |
| Operating expenses: | ||||
| Cost of sales | 39 | 33 | 147 | 63 |
| Research and development, including stock-based compensation of $1,384, $1,620, $2,753, and $3,194 respectively | 17,443 | 15,747 | 30,199 | 31,050 |
| Selling, general and administrative, including stock-based compensation of $1,952, $1,575, $3,661, and $3,044 respectively | 9,750 | 9,350 | 18,984 | 20,958 |
Item 1. Financial Statements
FAQ
- What is Lexicon Pharmaceuticals's business segments — revenue?
- Lexicon Pharmaceuticals (LXRX) reported business segments — revenue of $692K in Q2 2026.
- How has Lexicon Pharmaceuticals's business segments — revenue changed year-over-year?
- Lexicon Pharmaceuticals's business segments — revenue decreased by 97.6% year-over-year, from $28.87M to $692K.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — revenue?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — revenue has grown at a 610.3% compound annual growth rate (CAGR), from $139K to $49.8M.
- What does business segments — revenue mean?
- The total gross income generated by a specific business segment through its primary commercial activities, such as product sales or service delivery. This metric serves as the top-line indicator of market demand and commercial success for the segment's offerings. It provides a baseline for evaluating the segment's contribution to the overall enterprise revenue.
Ask your AI about Lexicon Pharmaceuticals's business segments — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude